NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3581.70 -1.90 (-0.05%)

79,064 NSE+BSE Volume

NSE 12 Sep, 2025 12:38 PM (IST)

121,221

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

24 Jul 2019

3581.70

-0.05%

Torrent Pharma: Results in line, OAI overhang

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

Karvy

In Q1FY20, Torrent Pharma's revenues have increased by 8% YoY to Rs 20220 mn (our estimates Rs 202380 mn).

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

23 Jul 2019

3581.70

-0.05%

Torrent Pharma

Hold: Torrent Pharmaceuticals Ltd.

Sharekhan

Q1FY2020 result of Torrent Pharmaceuticals Limited (Torrent Pharma) showed strong operational performance. Sales for the quarter were in line with estimates at Rs. 2,022 crore, 8% growth y-o-y. Operating profit was 4% above our estimate at Rs. 541 crore, reporting an improvement of 127 BPS y-o-y to 26.8%. Reported profit for the quarter was 8% above our estimate at Rs. 216 crore, showing robust 32.5% growth y-o-y. During the quarter, U.S. business reported 13% y-o-y growth and no new approvals were received during the quarter....

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3620.9

Torrent Pharmaceuticals Ltd.

23 Jul 2019

3581.70

-0.05%

Superior product mix and low base drive earnings

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

23 July 2019 USD54m (+13% YoY to INR3.8b), supported by new launches and restart of Losartan sales. India revenue grew moderately by 9% YoY to INR9.1b. However, Germany (+4% YoY to INR2.6b) and Brazil (-3% YoY to INR1.7b) businesses exhibited a muted performance. Gross margin improved 210bp YoY (+100bp QoQ) to 72%, as the company discontinued low-margin products in India and capitalized on opportunities in the US due to supply shortage. However, higher employee cost (+40bp YoY to 19.3% largely due to annual increments) and other expenses (+60bp YoY to 27.4%) restricted EBITDA margin expansion to 130bp YoY (26.8% v/s INR1.9b), led by improved margins and a lower tax rate. (a) TRP indicated US sales would come in flat YoY at ~USD220m in FY20 if Indrad also receives OAI (official action indicated) classification. (b) The company has gradually resumed losartan sales to the US market.

Sharekhan decreased Buy price target of Torrent Pharmaceuticals Ltd. to 4024.0 on 29 Aug, 2025.

Torrent Pharmaceuticals Ltd.

18 Jul 2019

3581.70

-0.05%

Torrent Pharma

Hold: Torrent Pharmaceuticals Ltd.

Sharekhan

Torrent Pharmaceuticals Limited's (Torrent Pharma's) Dahej plant was inspected by the USFDA between March 11-19, 2019. The company received Form 483 with five observations. USFDA classified this inspection to Official Action Indicated (OAI), indicating unsatisfactory response submitted by the company (for Form 483). OAI status does not impact the existing operations of the company. However, new product approvals could get delayed. If the issue is not resolved satisfactorily within the stipulated timeframe, it could result in escalation to a Warning...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

27 May 2019

3581.70

-0.05%

Company Update:Torrent Pharma.

Buy: Torrent Pharmaceuticals Ltd.

Axis Direct

Torrent Pharma (TRP IN) has demonstrated robust track record in domestic formulation by building its core competence around chronic and sub-chronic therapeutic area and witnessed healthy revenue growth of ~15% CAGR over FY14-19

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3620.9

Torrent Pharmaceuticals Ltd.

21 May 2019

3581.70

-0.05%

Torrent Pharma (4QFY19): Weak US outlook. Downgrade to NEUTRAL

Neutral: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

We believe TRP is not in faults for discontinuing the sales of two sartan products in the US as the USFDA has changed its rules related to sartan impurities frequently over FY19. Despite cutting our FY20/21E EPS estimates by 14/13% and downgrading the stock to Neutral on account of US, we maintain our target multiple at 24x P/E, as we remain constructive on TRP's lucrative India business which we value at Rs ~1,200/sh (70% of CMP). We believe the growth in India and other businesses will enable TRP to shed ~Rs 16bn net debt over the next two years, aiding ~35% EPS CAGR. Any overreaction on the stock in the near term should be taken as an opportunity to enter. We downgrade TRP to NEUTRAL following a 13% earnings cut owing to several headwinds in the US biz, which will persist over the next 4-6 quarters, in our view. Our revised TP is Rs 1,745/sh (24x FY21E EPS).

Sharekhan decreased Buy price target of Torrent Pharmaceuticals Ltd. to 4024.0 on 29 Aug, 2025.

Torrent Pharmaceuticals Ltd.

21 May 2019

3581.70

-0.05%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

India growth steady; acquisitions to enhance coverage Domestic branded formulations including CRAMs constitute 48% of sales. The acquisition of Elder Pharma's branded portfolio has added new therapies like neutraceuticals, gynaecology and helped fill up portfolio gaps. The Unichem acquisition has added branded portfolio comprising some power brands besides achievement of long term synergy benefits. We expect India sales to grow at ~9% CAGR in FY19-21E to | 3834 crore. US, Germany, Brazil key export destinations for company...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

21 May 2019

3581.70

-0.05%

Torrent Pharma - 4QFY19 Result Update

Torrent Pharmaceuticals Ltd.

Reliance Securities

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3310.4

Torrent Pharmaceuticals Ltd.

14 Mar 2019

3581.70

-0.05%

Model Trading Portfolio - Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd.

Edelweiss

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group.

Sharekhan decreased Buy price target of Torrent Pharmaceuticals Ltd. to 4024.0 on 29 Aug, 2025.

Torrent Pharmaceuticals Ltd.

12 Feb 2019, 12:00AM

3581.70

-0.05%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent reported a strong 39% YoY growth in revenue in Q3FY19 led by robust formulation sales growth across India, US and Germany. While, India business reported stellar performance with 42.5% YoY revenue growth led by acquisition of Unichem portfolio, US sales rose by 84% YoY led by volume growth, new launches and market share gains....

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3310.4

Is Torrent Pharmaceuticals Ltd. worth buying?

155 Votes:

Buy 74.19%

Sell 16.77%

Hold 9.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf